Document is current
Any future updates will be listed below
-
Authors
Jeung, Ye Sul
Lee, Wan Taek
Kim, Yejin
Keam, Bhumsuk
Kim, Tae Min
Park, Chul-Kee
Sim, Jin-Ah
Yoo, Shin Hye
-
Funding
Funding for this research was provided by:
Ministry of Health and Welfare (RS-2023-KH137917)
- License Information
-
More Information
Article History
Received: 13 November 2025
Accepted: 19 December 2025
First Online: 29 December 2025
Declarations
:
: This study was approved by the Institutional Review Board of Seoul National University Hospital (IRB No. 2305-088-1431), and the requirement for informed consent was waived due to the retrospective design and the use of de-identified data. All study procedures were carried out in accordance with the ethical principles of the Declaration of Helsinki.
: T.M.K.: Consultancy: AstraZeneca, BeOne Medicines, Daiichi Sankyo, Janssen, Merck KGaA, Novartis, Regeneron, Roche/Genentech, Samsung Bioepis, and Chong Kun Dang Pharmaceutical; Honoraria: AstraZeneca/MedImmune, Amgen, BeOne Medicines, Daiichi Sankyo, Janssen Research & Development, and Takeda. Otherwise, the authors have no disclosures.
